DDAVP in acquired von Willebrand syndrome associated with multiple myeloma.
The response to a single intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP, desmopressin) was studied in two patients with acquired von Willebrand syndrome associated with IgG-kappa myeloma. Following infusion of DDAVP (0.3-0.4 micrograms/kg), prolonged bleeding time was normalized; plasma ristocetin cofactor activity, von Willebrand factor antigen, and factor VIII activity were remarkably increased; and high-molecular-weight forms of von Willebrand factor were demonstrated by crossed immunoelectrophoresis in both patients. Excellent hemostasis was achieved following administration of DDAVP in one patient when it was used for the treatment of gum bleeding and for the prophylaxis of bleeding during and after dental extractions. These observations suggest that DDAVP is an effective alternative to blood products for at least some patients with acquired von Willebrand syndrome in addition to patients with inherited von Willebrand disease, hemophilia A, and uremia.
D001780:Blood Coagulation Tests; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006488:Hemostasis, Surgical; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007145:Immunoglobulin kappa-Chains; D007263:Infusions, Parenteral; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications*; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains; D003894:Deamino Arginine Vasopressin